JP2024523876A - 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤 - Google Patents

睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤 Download PDF

Info

Publication number
JP2024523876A
JP2024523876A JP2023577376A JP2023577376A JP2024523876A JP 2024523876 A JP2024523876 A JP 2024523876A JP 2023577376 A JP2023577376 A JP 2023577376A JP 2023577376 A JP2023577376 A JP 2023577376A JP 2024523876 A JP2024523876 A JP 2024523876A
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
ceutically acceptable
oxybutynin
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523876A5 (https=
Inventor
タラント－モンテムッロ，ルイージ
ファーカス，ロナルド
ホワイト，デービッド，ピー．
ミラー，ローレンス，ジー．
Original Assignee
アプニメッド，インコーポレイテッド（デラウェア）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプニメッド，インコーポレイテッド（デラウェア） filed Critical アプニメッド，インコーポレイテッド（デラウェア）
Publication of JP2024523876A publication Critical patent/JP2024523876A/ja
Publication of JP2024523876A5 publication Critical patent/JP2024523876A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023577376A 2021-06-17 2022-06-17 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤 Pending JP2024523876A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163211673P 2021-06-17 2021-06-17
US63/211,673 2021-06-17
US202263319035P 2022-03-11 2022-03-11
US63/319,035 2022-03-11
PCT/US2022/033987 WO2022266440A1 (en) 2021-06-17 2022-06-17 Norepinephrine reuptake inhibitors for treating sleep apnea

Publications (2)

Publication Number Publication Date
JP2024523876A true JP2024523876A (ja) 2024-07-02
JP2024523876A5 JP2024523876A5 (https=) 2025-06-24

Family

ID=82608262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577376A Pending JP2024523876A (ja) 2021-06-17 2022-06-17 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤

Country Status (10)

Country Link
US (1) US20240277719A1 (https=)
EP (1) EP4355333A1 (https=)
JP (1) JP2024523876A (https=)
KR (1) KR20240021920A (https=)
AU (1) AU2022294086A1 (https=)
BR (1) BR112023026158A2 (https=)
CA (1) CA3221848A1 (https=)
IL (1) IL309251A (https=)
MX (1) MX2023014709A (https=)
WO (1) WO2022266440A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106773A1 (en) * 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
GEAP202416602A (en) * 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
KR102874891B1 (ko) * 2018-01-30 2025-10-21 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
MX2021004883A (es) * 2018-10-31 2021-08-05 Apnimed Inc Delaware Metodos y composiciones para tratar apnea del sue?o.
CN118557736A (zh) * 2019-02-08 2024-08-30 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
US20240075035A1 (en) * 2021-01-14 2024-03-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
US20240277719A1 (en) 2024-08-22
MX2023014709A (es) 2024-01-15
BR112023026158A2 (pt) 2024-03-05
AU2022294086A1 (en) 2024-01-04
WO2022266440A1 (en) 2022-12-22
EP4355333A1 (en) 2024-04-24
CA3221848A1 (en) 2022-12-22
KR20240021920A (ko) 2024-02-19
IL309251A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
JP7422666B2 (ja) 睡眠時無呼吸を治療するための方法および組成物
JP2022519721A (ja) 睡眠時無呼吸を治療するための方法および組成物
CN117177741A (zh) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂和大麻素的组合
US20240075035A1 (en) Methods and compositions for treating sleep apnea
JP2024523876A (ja) 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤
US20240358709A1 (en) Methods and compositions for treating sleep apnea
US20230135373A1 (en) Methods and compositions for treating sleep apnea
US20250009720A1 (en) Methods and compositions for treating sleep apnea
CN117615764A (zh) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂
JP2025527796A (ja) 睡眠時無呼吸を治療するための方法及び組成物
JP2024511091A (ja) 睡眠時無呼吸を治療するための方法及び組成物
US20250302814A1 (en) Methods and compositions for treating sleep apnea
US20240139200A1 (en) Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
WO2024220343A1 (en) Combination of a norepinephrine reuptake inhibitor and a melatonin receptor agonist for use in treating sleep apnea
JP2025520386A (ja) カンナビノイドおよびカルボニックアンヒドラーゼ阻害剤の組合せを用いた睡眠時無呼吸を治療する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250616